⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28695270 | 0.79 | BTN3A1 (0.36) | — | |
| SCHEMBL30605 | 0.78 | TSHR (0.38) | — | |
| SCHEMBL2589130 | 0.75 | TSHR (0.33) | — | |
| SCHEMBL2557778 | 0.75 | TSHR (0.33) | — | |
| Butane SCHEMBL28193264 | 0.75 | TSHR (0.43) | — | |
| SCHEMBL1075958 | 0.74 | LPAR2 (0.31) | — | |
| SCHEMBL8746827 | 0.73 | TSHR (0.62) | — | |
| SCHEMBL45275 | 0.73 | MEN1 (0.30) | — | |
| SCHEMBL709420 | 0.73 | TSHR (0.62) | — | |
| Ammonia Solution, Strong SCHEMBL27666826 | 0.73 | TSHR (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6693090-B2 | OSTEOPOROSIS | AVENTIS PHARMA S.A. (FR) | 2004-02-17 | — | — | US | disclosed |
| US-20030073675-A1 | Novel 19-norsteroids substituted in position 11beta, preparation process and intermediates, application as medicines and pharmaceutical compositions containing them | AVENTIS PHARMA S.A. | 2003-04-17 | — | — | US | disclosed |
| US-6479476-B1 | TREATING MENOPAUSAL SYMPTOMS AND OSTEOPOROSIS IN FEMALE WARM-BLOODED ANIMALS | AVENTIS PHARMA S.A. (FR) | 2002-11-12 | — | — | US | disclosed |
| US-6472382-B2 | OSTEOPOROSIS TREATMENT | AVENTIS PHARMA S.A. (FR) | 2002-10-29 | — | — | US | disclosed |
| US-6462211-B1 | FOR USE IN HORMONE REPLACEMENT THERAPY, THERAPY OF OSTEOPOROSIS | AVENTIS PHARMA S.A. (FR) | 2002-10-08 | — | — | US | disclosed |
| US-6399766-B2 | TREATING OSTEOPOROSIS; HAVING NO ENDOMETRIAL HYPERPLASIA ACTIVITY NOR BREAST TUMOR PROLIFERATION ACTIVITY | AVENTIS PHARMA S.A. (FR) | 2002-06-04 | — | — | US | disclosed |
| US-20020040135-A1 | 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them | Roussel, Hoechst | 2002-04-04 | — | — | US | disclosed |
| US-20010039268-A1 | New 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them | HOECHST MARION ROUSSEL | 2001-11-08 | — | — | US | disclosed |
| US-20010008941-A1 | New 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them | HOECHST MARION ROUSSEL | 2001-07-19 | — | — | US | disclosed |
| US-20010005756-A1 | New 4-halogenated steroids, their preparation process and intermediates, their use as medicaments and the pharmaceutical compositions containing them | HOECHST MARION ROUSSEL | 2001-06-28 | — | — | US | disclosed |
| US-6239121-B1 | COMPOUNDS OTHER THAN OESTRADIOL HAVING A DISSOCIATED OESTROGEN ACTIVITY AT THE BONE LEVEL, WHILE HAVING NO OR LITTLE ENDOMETRIAL HYPERPLASIA ACTIVITY, NOR BREAST TUMOR PROLIFERATION ACTIVITY. | HOECHST MARION ROUSSEL (FR) | 2001-05-29 | — | — | US | disclosed |